<p>/PRNewswire/ -- <strong>BioArctic AB (publ)</strong>（纳斯达克斯德哥尔摩：BIOA B）<strong>今天宣布，公司已与礼来公司签署了一项研究与合作协议，涉及将 BioArctic 的专有 BrainTransporter 技术与一款未披露的礼来药物候选者结合的潜在新治疗方案。根据协议，BioArctic 将获得 3000 万美元的预付款。</strong></p>
<p>除了预付款外，BioArctic 还将有资格获得高达 7.7 亿美元的额外里程碑付款。如果该产品上市，BioArctic 还将有权获得未来全球产品销售的中等单数级别的分成权利。</p>
<p>在此次合作中，BioArctic 将生成一款结合 BrainTransporter 技术与礼来专有分子的新的药物候选者。礼来将承担该药物候选者及相关产品的全球开发和商业化的全部责任。</p>
<p>“我对今天的公告感到兴奋，并为一家大型制药公司看到了我们专有的 BrainTransporter 技术的潜力而感到自豪。礼来与我们有着相同的愿望，希望为严重神经系统疾病的患者做更多的事情，这次合作就是对此的证明，” BioArctic 首席执行官 Gunilla Osswald 说道。</p>
<p>这项协议是 BioArctic 与使用 BrainTransporter 技术的合作伙伴签署的第四个 [1] 合作协议。BioArctic 保留在这四项协议范围之外使用 BrainTransporter 平台的所有权利。BrainTransporter 平台可以用于多种不同的治疗领域，以将生物制剂和其他方式输送到大脑，为 BioArctic 提供许多潜在的未来合作机会。</p>
<p><em>本发布讨论了一种正在开发中的药物的研究性用途，并不旨在传达关于疗效或安全性的结论。没有保证该研究性药物将成功完成临床开发或获得健康主管部门的批准。</em></p>
<p><em>该信息是 BioArctic AB (publ) 根据欧盟市场滥用法规所需披露的信息。该信息于 2026 年 6 月 22 日 07:30 CET 通过以下联系人发布以供公众披露。</em></p>
<p><strong>如需更多信息，请联系：</strong></p>
<p>Oskar Bosson，副总裁，传播与投资者关系</p>
<p>电子邮件：oskar.bosson@bioarctic.se</p>
<p>电话：+46 70 410 71 80</p>
<p>Jenny Ljunggren，外部传播与投资者关系经理</p>
<p>电子邮件：jenny.ljunggren@bioarctic.com</p>
<p>电话：+46 76 013 86 08</p>
<p><strong>关于 BrainTransporter™技术</strong></p>
<p>BioArctic 的 BrainTransporter 技术是一种通过转铁蛋白受体（TfR）促进药物进入大脑的技术。药物通过血脑屏障的主动运输可以实现更广泛的大脑分布，从而提高疗效、改善安全性和用药便利性。该技术正在应用于多个内部药物项目以及外部合作中，并可能成为未来与其他制药公司合作的一部分。</p>
<p><strong>关于 BioArctic AB</strong></p>
<p>BioArctic AB (publ) 是一家瑞典的研究型生物制药公司，专注于创新治疗方案，以延缓或停止神经退行性疾病的进展。该公司发明了 Leqembi®（lecanemab）——全球首个被证明能够减缓疾病进展并减少早期阿尔茨海默病认知障碍的药物。Leqembi 是与 BioArctic 的合作伙伴 Eisai 共同开发的，Eisai 负责全球的监管互动和商业化。除了 Leqembi，BioArctic 还拥有广泛的研究组合，包括针对帕金森病和 ALS 的抗体以及针对阿尔茨海默病的其他项目。多个项目利用了该公司的专有 BrainTransporter™技术，该技术有潜力主动运输抗体穿过血脑屏障，以增强治疗的疗效。BioArctic 的 B 股（BIOA B）在纳斯达克斯德哥尔摩大盘上市。有关更多信息，请访问 www.bioarctic.se。</p>
<p>[1] 之前的协议包括与 Eisai 的 BAN2802 研究评估协议、与百时美施贵宝的 BioArctic PyroGlutamate-淀粉样β抗体项目的全球许可协议，以及与诺华的选项、合作与许可协议。</p>
<p>该信息由 Cision 提供 http://news.cision.com</p>
<p>https://news.cision.com/bioarctic/r/bioarctic-and-lilly-sign-research-and-collaboration-agreement-combining-lilly-compound-with-bioarcti,c4365925</p>
<p>以下文件可供下载：</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>https://mb.cision.com/Main/9978/4365925/4160828.pdf</td>
<td>BioArctic 与礼来签署研究与合作协议，将礼来化合物与 BioArctic 的 BrainTransporter™技术结合</td>
</tr>
</tbody>
</table>
<p>来源：BioArctic</p>

礼来

2 倍做多 LLY ETF - Direxion

1 倍做空 LLY ETF - Direxion

LLYZ

2 倍做多 LLY ETF - Defiance

<p>BioArctic AB 宣布与礼来达成一项研究与合作协议，将 BioArctic 的 BrainTransporter 技术与一款未披露的礼来药物候选者结合，用于神经退行性疾病的治疗。BioArctic 收到 3000 万美元的预付款，潜在的里程碑付款可达 7.7 亿美元，以及分级版税。礼来负责全球开发和商业化。这标志着使用 BrainTransporter 平台的第四次合作</p>

<p>, /PRNewswire/ -- <strong>BioArctic AB (publ)</strong>(NASDAQ STOCKHOLM: BIOA B) <strong>today announced that the company has entered into a research and collaboration agreement with Eli Lilly and Company regarding a potential new treatment combining BioArctic's proprietary BrainTransporter technology with an undisclosed Lilly drug candidate in neurodegeneration. As part of the agreement, BioArctic will receive USD 30 million in upfront payment.</strong></p>
<div class="lb-trans"><p>/PRNewswire/ -- <strong>BioArctic AB (publ)</strong>（纳斯达克斯德哥尔摩：BIOA B）<strong>今天宣布，公司已与礼来公司签署了一项研究与合作协议，涉及将 BioArctic 的专有 BrainTransporter 技术与一款未披露的礼来药物候选者结合的潜在新治疗方案。根据协议，BioArctic 将获得 3000 万美元的预付款。</strong></p>
</div><p>In addition to the upfront payment, BioArctic will be eligible to receive additional milestone payments of up to USD 770 million. BioArctic will also be entitled to tiered mid-single digit royalties on future global product sales if the product reaches the market.</p>
<div class="lb-trans"><p>除了预付款外，BioArctic 还将有资格获得高达 7.7 亿美元的额外里程碑付款。如果该产品上市，BioArctic 还将有权获得未来全球产品销售的中等单数级别的分成权利。</p>
</div><p>Under the collaboration, BioArctic will generate a new drug candidate combining the BrainTransporter technology with a Lilly proprietary molecule. Lilly will assume full responsibility for the global development and commercialization of the drug candidate and related products.</p>
<div class="lb-trans"><p>在此次合作中，BioArctic 将生成一款结合 BrainTransporter 技术与礼来专有分子的新的药物候选者。礼来将承担该药物候选者及相关产品的全球开发和商业化的全部责任。</p>
</div><p>&#34;I'm excited by today's announcement and proud that a large pharmaceutical company sees potential in our proprietary BrainTransporter technology. Lilly shares our ambition to do more for patients with severe neurological disorders, and this collaboration is a testament to that,&#34; said Gunilla Osswald, CEO at BioArctic.</p>
<div class="lb-trans"><p>“我对今天的公告感到兴奋，并为一家大型制药公司看到了我们专有的 BrainTransporter 技术的潜力而感到自豪。礼来与我们有着相同的愿望，希望为严重神经系统疾病的患者做更多的事情，这次合作就是对此的证明，” BioArctic 首席执行官 Gunilla Osswald 说道。</p>
</div><p>This agreement is the fourth[1] collaboration BioArctic has entered into with partners using the BrainTransporter technology. BioArctic retains all rights for use of the BrainTransporter platform outside of the scope of these four agreements. The BrainTransporter platform can be used in a multitude of different therapy areas for delivery of biologics and other modalities to the brain, giving BioArctic many potential future partnering opportunities.</p>
<div class="lb-trans"><p>这项协议是 BioArctic 与使用 BrainTransporter 技术的合作伙伴签署的第四个 [1] 合作协议。BioArctic 保留在这四项协议范围之外使用 BrainTransporter 平台的所有权利。BrainTransporter 平台可以用于多种不同的治疗领域，以将生物制剂和其他方式输送到大脑，为 BioArctic 提供许多潜在的未来合作机会。</p>
</div><p><em>This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that such investigational agent will successfully complete clinical development or gain health authority approval.</em></p>
<div class="lb-trans"><p><em>本发布讨论了一种正在开发中的药物的研究性用途，并不旨在传达关于疗效或安全性的结论。没有保证该研究性药物将成功完成临床开发或获得健康主管部门的批准。</em></p>
</div><p><em>This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact persons below, on June 22, 2026, at 07.30 a.m. CET.</em></p>
<div class="lb-trans"><p><em>该信息是 BioArctic AB (publ) 根据欧盟市场滥用法规所需披露的信息。该信息于 2026 年 6 月 22 日 07:30 CET 通过以下联系人发布以供公众披露。</em></p>
</div><p><strong>For further information, please contact:</strong></p>
<div class="lb-trans"><p><strong>如需更多信息，请联系：</strong></p>
</div><p>Oskar Bosson, VP Communications and IR</p>
<div class="lb-trans"><p>Oskar Bosson，副总裁，传播与投资者关系</p>
</div><p>E-mail: oskar.bosson@bioarctic.se</p>
<div class="lb-trans"><p>电子邮件：oskar.bosson@bioarctic.se</p>
</div><p>Phone: +46 70 410 71 80</p>
<div class="lb-trans"><p>电话：+46 70 410 71 80</p>
</div><p>Jenny Ljunggren, External Communications and Investor Relations Manager</p>
<div class="lb-trans"><p>Jenny Ljunggren，外部传播与投资者关系经理</p>
</div><p>E-mail: jenny.ljunggren@bioarctic.com</p>
<div class="lb-trans"><p>电子邮件：jenny.ljunggren@bioarctic.com</p>
</div><p>Telephone: +46 76 013 86 08</p>
<div class="lb-trans"><p>电话：+46 76 013 86 08</p>
</div><p><strong>About the BrainTransporter™ technology</strong></p>
<div class="lb-trans"><p><strong>关于 BrainTransporter™技术</strong></p>
</div><p>BioArctic's BrainTransporter technology is a technology for facilitating the passage of drugs into the brain using the transferrin receptor (TfR). Active transport of medicines across the blood-brain barrier can result in broader brain distribution enabling better efficacy, improved safety profile and dosing convenience. The technology is being applied to several in-house drug projects, as well as external collaborations, and could become part of future collaborations with other pharma companies.</p>
<div class="lb-trans"><p>BioArctic 的 BrainTransporter 技术是一种通过转铁蛋白受体（TfR）促进药物进入大脑的技术。药物通过血脑屏障的主动运输可以实现更广泛的大脑分布，从而提高疗效、改善安全性和用药便利性。该技术正在应用于多个内部药物项目以及外部合作中，并可能成为未来与其他制药公司合作的一部分。</p>
</div><p><strong>About BioArctic AB</strong></p>
<div class="lb-trans"><p><strong>关于 BioArctic AB</strong></p>
</div><p>BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company invented Leqembi® (lecanemab) – the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with BioArctic's partner Eisai, who are responsible for regulatory interactions and commercialization globally. In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson's disease and ALS as well as additional projects against Alzheimer's disease. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which has the potential to actively transport antibodies across the blood-brain barrier to enhance the efficacy of the treatment. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For further information, please visit www.bioarctic.se.</p>
<div class="lb-trans"><p>BioArctic AB (publ) 是一家瑞典的研究型生物制药公司，专注于创新治疗方案，以延缓或停止神经退行性疾病的进展。该公司发明了 Leqembi®（lecanemab）——全球首个被证明能够减缓疾病进展并减少早期阿尔茨海默病认知障碍的药物。Leqembi 是与 BioArctic 的合作伙伴 Eisai 共同开发的，Eisai 负责全球的监管互动和商业化。除了 Leqembi，BioArctic 还拥有广泛的研究组合，包括针对帕金森病和 ALS 的抗体以及针对阿尔茨海默病的其他项目。多个项目利用了该公司的专有 BrainTransporter™技术，该技术有潜力主动运输抗体穿过血脑屏障，以增强治疗的疗效。BioArctic 的 B 股（BIOA B）在纳斯达克斯德哥尔摩大盘上市。有关更多信息，请访问 www.bioarctic.se。</p>
</div><p>[1] Previous agreements include a research evaluation agreement regarding BAN2802 with Eisai, a global license agreement with Bristol Myers Squibb for BioArctic's PyroGlutamate-amyloid-beta antibody program and an option, collaboration and license agreement with Novartis.</p>
<div class="lb-trans"><p>[1] 之前的协议包括与 Eisai 的 BAN2802 研究评估协议、与百时美施贵宝的 BioArctic PyroGlutamate-淀粉样β抗体项目的全球许可协议，以及与诺华的选项、合作与许可协议。</p>
</div><p>This information was brought to you by Cision http://news.cision.com</p>
<div class="lb-trans"><p>该信息由 Cision 提供 http://news.cision.com</p>
</div><p>https://news.cision.com/bioarctic/r/bioarctic-and-lilly-sign-research-and-collaboration-agreement-combining-lilly-compound-with-bioarcti,c4365925</p>
<div class="lb-trans"><p>https://news.cision.com/bioarctic/r/bioarctic-and-lilly-sign-research-and-collaboration-agreement-combining-lilly-compound-with-bioarcti,c4365925</p>
</div><p>The following files are available for download:</p>
<div class="lb-trans"><p>以下文件可供下载：</p>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>https://mb.cision.com/Main/9978/4365925/4160828.pdf</td>
<td>BioArctic and Lilly sign research and collaboration agreement combining Lilly compound with BioArcticâ€™s BrainTransporterâ„¢ technology</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>https://mb.cision.com/Main/9978/4365925/4160828.pdf</td>
<td>BioArctic 与礼来签署研究与合作协议，将礼来化合物与 BioArctic 的 BrainTransporter™技术结合</td>
</tr>
</tbody>
</table>
</div><p>SOURCE BioArctic</p>
<div class="lb-trans"><p>来源：BioArctic</p>
</div>

BioArctic and Lilly sign research and collaboration agreement combining Lilly compound with BioArctic's BrainTransporter™ technology | B Stock News

StockTitan

Defiance Daily Target 2X Short LLY ETF

Eisai Co., Ltd.

百时美施贵宝

诺华制药

Bristol-Myers Squibb Company

Novartis AG

BioArctic 与礼来公司签署研究与合作协议，将礼来的化合物与 BioArctic 的 BrainTransporter™技术结合 | B 股新闻